Novartis' Cosentyx Approved for Juvenile ERA and Psoriatic Arthritis

CompilationFan Dongdong

The U.

This FDA approval marks the first time the biologic Cosentyx has been approved for ERA

The latest approval of Cosentyx is based on the Phase III study of JUNIPERA, a 2-year, three-part, double-blind, placebo-controlled, randomized withdrawal Phase 3 study that enrolled 86 patients aged 2 to 17 years, Children and adolescents with a diagnosis of JPsA or ERA according to the International Federation of Rheumatology Association classification criteria

The study showed that in pediatric patients treated with Cosentyx for both indications, an 85% lower risk of relapse was found in adolescent patients with PsA and a 53% lower risk in adolescent patients with ERA

Currently, treatment options to help improve joint inflammation, dactylitis, and enthesitis are very limited for this population

Cosentyx is an inhibitor of interleukin-17A (IL-17A), which is produced by various cells from the innate immune system (which can be triggered by mechanical stress) and the adaptive immune system

The FDA approval of Cosentyx further strengthens Novartis' commitment to the pediatric community, Victor Bulto, head of Novartis' U.

In addition to the U.

Reference source: Novartis Drug Approved for Juvenile ERA and Psoriatic Arthritis